CVS Health (CVS) Tops Q3 EPS by 9c, Beats on Revenue; Offers FY22 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
'Several De-Risking Events Positive' for CVS Health (CVS) - Mizuho
November 2, 2022 12:58 PM EDTMizuho Securities analyst Ann Hynes reiterated a Buy rating and $120.00 price target on CVS Health (NYSE: CVS) following Q3 results as several de-risking events are positive for the stock.
The analyst commented, "CVS announced 1) good Q3:22 earnings, 2) provided 2023 initial 2023 EPS guidance of -3.5%... More
